Peter Libby MDMallinckrodt Professor of Medicine, Harvard Medical School; Cardiovascular Specialist, Brigham and Women’s Hospital, Boston, Massachusetts
Dr. Libby received his medical degree from the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) in Boston, Massachusetts. He also holds an honorary Master of Arts degree from Harvard University, Cambridge, Massachusetts, and honorary doctorates from the University of Lille, France, from Laval University in Québec Canada, and from J.W. Goethe Universität, Frankfurt am Main, Germany. He served as the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital from 1998 through 2014. He is currently the Mallinckrodt Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
Dr. Libby has received numerous awards and recognitions for his research accomplishments including the Gold Medal of the European Society of Cardiology and the Basic Research Prize of the American Heart Association in 2011; the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society in 2013; the Special Award of the Heart Failure Association of the European Society of Cardiology in 2014; the Ernst Jung Gold Medal for Medicine for 2016; and the Earl Benditt Award of the North American Vascular Biology Organization in 2017. In 2018 he received the Arthur S. Agatston Cardiovascular Disease Prevention Award from the Society of Cardiovascular Computed Tomography. He received the Honorary Award for the Lecture on Clinical Science from the German Cardiac Society in 2019. He received the Paul Dudley White Award from the American Heart Association in 2020. He was chosen as the Shimamoto Memorial Lecturer of the Japanese Atherosclerosis Society in 2021. He has been selected for the Eugene Braunwald Lectureship at the American College of Cardiology Scientific Sessions in 2022. He has garnered a number of lifetime achievement awards from various organizations and has delivered over 150 named or keynote lectures worldwide.
His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.
He has published extensively in medical journals, including Circulation and The New England Journal of Medicine, among others. He is also active in many organizations, including the American College of Cardiology and the American Heart Association, and was elected to the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists, where he served as President.
Dr. Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron. Dr. Libby is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc.
Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis. Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics.
Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.Funding
Dr. Libby receives funding support from the National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, and 1R01HL163099-01), the American Heart Association (18CSA34080399), the RRM Charitable Fund, and the Simard Fund.
Recent Contributions to PracticeUpdate:
- ACC 2023: Recommendations From Dr. Peter Libby
- The PCSK9 Pleitropy Paradox
- PCSK9 Inhibition During the Inflammatory Stage of COVID-19
- 2022 Top Story in Cardiology: Stabilization of Human Atherosclerotic Plaques — Dream or Reality?
- ESC 2022: Recommendation From Dr. Peter Libby
- Inflammation Drives Residual Risk in Chronic Kidney Disease
- Hematopoietic Loss of Y Chromosome Leads to Cardiac Fibrosis and Heart Failure Mortality
- Effect of Alirocumab Added to High-Intensity Statin on Coronary Atherosclerosis in Patients With AMI
- ACC 2022: Recommendations From Dr. Peter Libby
- Caffeine Blocks SREBP2-Induced Hepatic PCSK9 Expression to Enhance LDLR-Mediated Cholesterol Clearance